- Home
- VERU vs ENTA Comparison
VERU vs ENTA Comparison
Compare VERU & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- ENTA
- Stock Information
- Founded
- VERU 1971
- ENTA 1995
- Country
- VERU United States
- ENTA United States
- Employees
- VERU N/A
- ENTA N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- ENTA Health Care
- Exchange
- VERU Nasdaq
- ENTA Nasdaq
- Market Cap
- VERU 108.8M
- ENTA 129.3M
- IPO Year
- VERU 1990
- ENTA 2013
- Fundamental
- Price
- VERU $0.98
- ENTA $5.25
- Analyst Decision
- VERU Strong Buy
- ENTA Buy
- Analyst Count
- VERU 4
- ENTA 4
- Target Price
- VERU $4.00
- ENTA $17.25
- AVG Volume (30 Days)
- VERU 2.2M
- ENTA 759.5K
- Earning Date
- VERU 02-06-2025
- ENTA 02-05-2025
- Dividend Yield
- VERU N/A
- ENTA N/A
- EPS Growth
- VERU N/A
- ENTA N/A
- EPS
- VERU N/A
- ENTA N/A
- Revenue
- VERU $16,886,419.00
- ENTA $67,635,000.00
- Revenue This Year
- VERU N/A
- ENTA $8.11
- Revenue Next Year
- VERU N/A
- ENTA N/A
- P/E Ratio
- VERU N/A
- ENTA N/A
- Revenue Growth
- VERU 3.62
- ENTA N/A
- 52 Week Low
- VERU $0.36
- ENTA $4.71
- 52 Week High
- VERU $1.92
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- VERU 74.65
- ENTA 33.14
- Support Level
- VERU $0.70
- ENTA $4.71
- Resistance Level
- VERU $0.81
- ENTA $5.73
- Average True Range (ATR)
- VERU 0.11
- ENTA 0.35
- MACD
- VERU 0.02
- ENTA 0.08
- Stochastic Oscillator
- VERU 95.26
- ENTA 36.99
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.